LAUSR

Key Points Question When are the clinical benefits of the sodium glucose cotransporter 2 inhibitor dapagliflozin first apparent among patients with heart failure with mildly reduced or preserved ejection fraction? Findings In this prespecified secondary analysis of the DELIVER trial including 6263 patients, dapagliflozin resulted in rapid and substantial reductions in the primary end point of cardiovascular death or worsening heart failure, with first statistical significance attained within 2 weeks of randomization; these benefits were sustained until final trial follow-up. Meaning In this study, dapagliflozin led to early and sustained reductions in clinical events in patients with heart failure with mildly reduced or preserved ejection fraction.